The Most Frequent TEAEs
The 5 evaluated TEAEs were: nausea, nasopharyngitis, upper respiratory tract infection, headache, and hypertension. The Analysis Set for exposure-safety included pooled Phase 2 and Phase 3 subjects with RA who received filgotinib and had evaluable PopPK-based exposure estimates (AUC0-24) (N = 2678 for filgotinib and N = 2707 for GS-829845). Data were not included in the analysis if they were collected after subjects were rerandomized and were switched to a different treatment group. As shown in Figure 4 (filgotinib) and Figure 5 (GS-829845), filgotinib or GS-829845 exposures (AUC0-24) in subjects with RA were similar regardless of the presence (black) or absence (gray) of the evaluated TEAEs up to Week 52.